There's a saying that goes: "The market can remain irrational longer than you can remain solvent."
Sure, this trial is just about repeating what's been done before with greater statistical power, and there's a lot less question marks this time around, but you never know how the market might react anyways.
Rather than wonder about results (which I highly doubt will be much different from the 20 dose non-memantine patients in the last trial), I think the bigger question is what investors will think about it a year from now.
I think one of the reasons for why this stock is so cheap is because most investors still think of the headlines from last year when they hear about Neurotrope. By releasing the top-line data too early they managed to make themselves look like a scam trying to sell nonsignificant results as "positive results". The company being created through a reverse merger by a convicted securities fraudster doesn't exactly instill more confidence either.
The way I look at it, this stock is going to stay cheap until Neurotrope manages to fix its PR problem.
Hopefully the new CEO will figure out how to get people interested in the company again before it needs to raise more funds.
News 
Market Data 
Discover 
AI
